(AFP) Richard Hatchett, general manager of the Coalition for Epidemic Preparedness Innovations (Cepi), is “concerned”: His job is to ensure that future COVID-19 vaccines are distributed fairly around the world, but the United States, Europe, and the rest of the rich countries have already monopolized the first doses.
Even before the clinical trials of the experimental vaccines have concluded, some developed countries (the United States, the European Union, the United Kingdom, Canada, Japan) have commissioned a total of at minus 3.1 billion doses, according to an AFP count.
United States President Donald Trump blazed this particular trail: His administration signed contracts guaranteeing at least 800 million doses from six manufacturers for a population of 330 million, to be delivered starting at the end of the year for some of the doses.
“The US is potentially in a situation of oversupply if all of the vaccines that they’ve invested in are successful,” Hatchett told Agence France-Presse (AFP).
Hatchett said he understood national leaders are serving their own people as a priority, but called on Washington to behave like a global leader and share its doses with other countries.
“What we need to persuade global leaders is that as a vaccine becomes available in these initially limited quantities, it needs to be shared globally, that it shouldn’t be the case that just a handful of countries get all of the vaccines that is available in the first half of 2021,” said Hatchett, who wants at all costs to avoid the scenario of 2009, when rich countries managed to bag the first vaccines of the H1N1 flu.
An initiative named Covax and backed by the World Health Organization, as well as CEPI and the global vaccine alliance group Gavi, aims to buy and equitably distribute two billion doses in 2021. Ninety-two developing countries and 80 developed countries have signed on, and the European Union on Monday (Aug 31) announced a contribution of 400 million euros (US$473 million).
But the United States is refusing to join the effort.
“We will not be constrained by multilateral organizations influenced by the corrupt World Health Organization and China,” said White House spokesman Judd Deere on Tuesday.
ORDER OF PRIORITY?
Covax has only managed to secure 300 million doses to date from AstraZeneca, the pharmaceutical group that also signed separate partnership deals with the United States, Europe, Russia, South Korea, China, Latin America and Brazil. Novavax, a US biotech company, says it has formed a partnership with an Indian group to produce up to a billion doses of its potential vaccine in India.
CEPI’s negotiations, mainly funded by public and private donations, including from the Gates Foundation, are “ongoing” with other laboratories, but no deal has been announced, not even with the US firm Moderna, in which CEPI invested very early. The several million dollars given to Moderna are no match for the US$2.5 billion invested subsequently by the US government.
“While we have stayed in close touch with Moderna… for that small scale early stage agreement, you can’t have those kinds of commitments,” said Dr Hatchett.
The ideal goal for the WHO is that every country receives vaccinations for 20% of its population, starting with the most vulnerable people no matter what their nationality, including health workers.
Despite the competition, Covax hopes that with 172 members, the initiative will be able to negotiate good prices.
“That’s one of the reasons that we are asking countries to now make their commitments to the facility so that we know on behalf of how many countries we’re negotiating,” said Dr Hatchett. “The more countries that negotiate together, the stronger the purchasing power, and the easier the price.”
But the European Union is striking its own accords with laboratories, with 1.3 billion doses already acquired, and has not yet said if it will use the WHO facility.
In the longer term, Hatchett says that CEPI still has to raise between US$700 and US$800 million remaining of the US$2.1 billion needed to continue the vaccine research, because there is no guarantee that any of the vaccines currently under development will actually work. AFP